Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.75 CAD | 0.00% | -2.86% | +20.25% |
Apr. 08 | HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA | CI |
Mar. 14 | Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.25% | 110M | |
+15.65% | 70.36B | |
+2.72% | 25.18B | |
+6.36% | 8.61B | |
+6.10% | 8.14B | |
-21.85% | 7.83B | |
+0.18% | 4.56B | |
+17.40% | 4.32B | |
-0.14% | 4.06B | |
-2.61% | 3.87B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Brief: Obtains Public Reimbursement for Vascepa in Quebec